Michigan is currently home to 2241 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Ann Arbor, Detroit, Grand Rapids and Kalamazoo. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK Inhibitor
NCT06241118
Recruiting
This is a parallel group, Phase 3, multinational, multicenter, randomized, double-blind, placebo-controlled, 3-arm study for treatment of participants diagnosed with moderate-to-severe AD on background TCS who have had inadequate response to prior biologic or oral JAKi therapy. The purpose of this study is to measure the efficacy and safety of treatment with amlitelimab solution for subcutaneous (SC) injection compared with placebo in participants with moderate-to-severe AD aged 12 years and ol... Read More
Gender:
ALL
Ages:
12 years and above
Trial Updated:
07/15/2025
Locations: University of Michigan Medical Center- Site Number : 8401290, Ann Arbor, Michigan
Conditions: Dermatitis Atopic
Register for Updates
A Randomized Comparison of Stage-Based Care Versus Risk Factor-Based Care for Prevention of Cardiovascular Events
NCT06112418
Recruiting
TRANSFORM is a prospective, randomized, open blinded endpoint (PROBE), event-driven, pragmatic trial in patients who are at increased risk for atherosclerotic cardiovascular (CV) disease but with no known symptomatic CV disease. The trial tests the hypothesis that a Cleerly Coronary Artery Disease (CAD) Staging System-based care strategy reduces CV events compared with risk factor-based care.
Gender:
ALL
Ages:
55 years and above
Trial Updated:
07/15/2025
Locations: Henry Ford Hospital, Detroit, Michigan
Conditions: Diabetes Mellitus, Type 2, PreDiabetes, Metabolic Syndrome
Register for Updates
CTSN Embolic Protection Trial
NCT06027788
Recruiting
This is a prospective, multi-center, randomized effectiveness trial of the CardioGard Embolic Protection Cannula in high-risk valve surgery patients.
Gender:
ALL
Ages:
60 years and above
Trial Updated:
07/15/2025
Locations: University of Michigan, Ann Arbor, Michigan
Conditions: Delirium, Ischemic Stroke, Acute Kidney Injury, Heart Valve Disease, Coronary Artery Disease
Register for Updates
A Study to Learn How Well Dupilumab Works in Adult and Adolescent Participants With Eosinophilic Gastritis With or Without Eosinophilic Duodenitis and the Side Effects it May Have
NCT05831176
Recruiting
This study is researching an experimental drug called dupilumab. The study is focused on participants with active eosinophilic gastritis (EoG) with or without eosinophilic duodenitis (EoD). Participants with EoD only are not eligible for enrollment. EoG and EoD are uncommon, persistent, allergic/immune diseases in which eosinophils (a type of white blood cell) gather in large numbers in the stomach and small intestine and cause inflammation and damage. The aim of the study is to evaluate the ef... Read More
Gender:
ALL
Ages:
12 years and above
Trial Updated:
07/15/2025
Locations: University of Michigan, Ann Arbor, Michigan
Conditions: Eosinophilic Gastritis (EoG), Eosinophilic Duodenitis (EoD), Eosinophilic Gastrointestinal Disease (EGID), Eosinophilic Gastroenteritis
Register for Updates
Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), and the RNR Inhibitor BBI-825, in Subjects With Tumors With Oncogene Amplifications
NCT05827614
Recruiting
BBI-355 is an oral, potent, selective checkpoint kinase 1 (or CHK1) small molecule inhibitor in development as an ecDNA (extrachromosomal DNA) directed therapy (ecDTx). BBI-825 is an oral, potent, selective ribonucleotide reductase (or RNR) small molecule inhibitor. This is a first-in-human, open-label, 2-part, Phase 1/2 study to determine the safety profile and identify the maximum tolerated dose and recommended Phase 2 dose of BBI-355 administered as a single agent or in combination with BBI-8... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/15/2025
Locations: START Midwest, Grand Rapids, Michigan
Conditions: Triple Negative Breast Cancer (TNBC), High Grade Serous Ovarian Carcinoma, High Grade Endometrial Carcinoma, Anogenital Cancer, Head and Neck (HNSCC), Cutaneous Squamous Cell Carcinoma (CSCC), Cervical Squamous Cell Carcinoma, ER+ Breast Cancer, Leiomyosarcoma (LMS), Undifferentiated Pleomorphic Sarcoma (UPS), Pancreatic Cancer Metastatic, Small Cell Lung Cancer
Register for Updates
Renal Mechanism of SGLT2 Inhibition
NCT05507892
Recruiting
Canagliflozin is an oral drug which is currently approved for use in patients with type 2 diabetes by the US Food and Drug Administration (FDA). Canagliflozin acts by increasing salt and sugar loss in the urine, and has shown to protect heart, kidney, and blood vessel function in patients with type 2 diabetes. However, it is unknown how canagliflozin protects the kidneys from disease. Therefore, this study plans to learn more about how canagliflozin works to protect against diabetic kidney disea... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
07/15/2025
Locations: University of Michigan, Ann Arbor, Michigan
Conditions: Type 2 Diabetes, Diabetic Kidney Disease
Register for Updates
Prospective Case Collection Study for New Mammography Technologies
NCT05199701
Recruiting
To evaluate the safety and efficacy of the proposed investigational device and assess its clinical utility in breast cancer screening and diagnosis to support continuing technology development of the investigational technology.
Gender:
FEMALE
Ages:
Between 35 years and 100 years
Trial Updated:
07/15/2025
Locations: Corewell Health, Grand Rapids, Michigan
Conditions: Mammography
Register for Updates
RA-PRO PRAGMATIC TRIAL
NCT04692493
Recruiting
The 2021 ACR RA treatment guideline, based on widely acknowledged low to moderate quality evidence, recommends switching to a non-tumor necrosis factor (TNFi) biologic (choose among existing medications, currently, rituximab, abatacept, tocilizumab, or sarilumab) or a targeted synthetic DMARD arm (tsDMARD; choose among existing medications, currently, tofacitinib, baricitinib, upadacitinib) in patients with active RA despite the use of a TNFi-biologic. In practice, most patients receive another... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/15/2025
Locations: American Arthritis and Rheumatology Associates -Mi PLLC, Okemos, Michigan
Conditions: Rheumatoid Arthritis
Register for Updates
PPMI Clinical - Establishing a Deeply Phenotyped PD Cohort
NCT04477785
Recruiting
The Parkinson Progression Marker Initiative (PPMI) is a longitudinal, observational, multi-center natural history study to assess progression of clinical features, digital outcomes, and imaging, biologic and genetic markers of Parkinson's disease (PD) progression in study participants with manifest PD, prodromal PD, and healthy controls. The overall goal of PPMI is to identify markers of disease progression for use in clinical trials of therapies to reduce progression of PD disability.
Gender:
ALL
Ages:
30 years and above
Trial Updated:
07/15/2025
Locations: University of Michigan, Ann Arbor, Michigan
Conditions: Parkinson Disease
Register for Updates
TRAIN-BW: Backward Walking Training in Multiple Sclerosis
NCT04091464
Recruiting
Individuals with multiple sclerosis (MS) experience in impairments in mobility and cognition that increase the risk for accidental falls. More than 50% of individuals with MS experience injurious falls within a 6-month period. Current interventions to improve fall risk have focused on forward walking (FW) and balance training, resulting in small declines in the relative risk for falls with a large degree of variability. Interestingly, motor differences between MS and healthy controls are more pr... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/15/2025
Locations: Wayne State University, Detroit, Michigan
Conditions: Multiple Sclerosis, Gait Disorders, Neurologic, Accidental Fall
Register for Updates
Observational Study of Pediatric Rheumatic Diseases: The CARRA Registry
NCT02418442
Recruiting
Continuation of the CARRA Registry as described in the protocol will support data collection on patients with pediatric-onset rheumatic diseases. The CARRA Registry will form the basis for future CARRA studies. In particular, this observational registry will be used to answer pressing questions about therapeutics used to treat pediatric rheumatic diseases, including safety questions.
Gender:
ALL
Ages:
21 years and below
Trial Updated:
07/15/2025
Locations: University of Michigan, Ann Arbor, Michigan
Conditions: Rheumatic Joint Disease
Register for Updates
Comparing Single-Session Therapies for Chronic Pain
NCT07008105
Recruiting
Many people in the US suffer from chronic pain. Often times, individuals who have chronic pain also feel depressed, anxious, or hopeless, which can worsen pain. Psychologists, therefore, have developed several treatments to help people with chronic pain. These psychological treatments differ. The most common treatment is Cognitive Behavioral Therapy (CBT) for chronic pain, which helps patients better manage pain through changing thoughts and behaviors. Two newer, less common psychological therap... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/14/2025
Locations: Wayne State University, Detroit, Michigan
Conditions: Chronic Musculoskeletal Pain
Register for Updates